Cdkn1b Knockout cell line(RAW 264.7)
Catalog Number: KO01213
Price: Online Inquiry
Catalog Number: KO01213
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Cdkn1b Knockout cell line(RAW 264.7) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | monocyte-like, Adherent cells |
Passage ratio | 1:2-1:3 |
species | Mouse |
Gene | Cdkn1b |
Gene ID | 12576 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 90%DMEM+10%FBS |
Parental Cell Line | RAW 264.7 |
Quality Control | Genotype: Cdkn1b Knockout cell line(RAW 264.7) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | cyclin dependent kinase inhibitor 1Bprovided by MGI |
Also known as | p27; Kip1; p27Kip1 |
Gene Description | Enables cyclin binding activity and cyclin-dependent protein serine/threonine kinase inhibitor activity. Involved in several processes, including G1/S transition of mitotic cell cycle; heart development; and negative regulation of cardiac muscle tissue regeneration. Acts upstream of or within several processes, including negative regulation of cyclin-dependent protein serine/threonine kinase activity; negative regulation of epithelial cell proliferation involved in prostate gland development; and positive regulation of microtubule polymerization. Located in cytosol and nucleus. Is expressed in several structures, including brain; genitourinary system; heart and pericardium; hemolymphoid system; and sensory organ. Human ortholog(s) of this gene implicated in acute myeloid leukemia; breast cancer; multiple endocrine neoplasia type 4; and myelodysplastic syndrome. Orthologous to human CDKN1B (cyclin dependent kinase inhibitor 1B). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Ubiquitous expression in thymus adult (RPKM 30.0), ovary adult (RPKM 20.3) and 28 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.